Table 3.

Proportion of patients who met or exceeded MCIDs at 12 months

MCID	Overall population (N = 1570)a	Disease activity group				p valueb
		Sustained remission/LDA (N = 585)	Improving remission/LDA (N = 239)	Worsening M/HDA (N = 190)	Sustained M/HDA (N = 556)
mHAQ, N = 1544
%	36.9	41.6	42.4	33.2	30.9	0.0004
[95% CI]c	[0.3444, 0.3931]	[0.3750, 0.4572]	[0.3597, 0.4908]	[0.2640, 0.4046]	[0.2704, 0.3490]
Patient pain, N = 1565
%	55.0	69.6	58.6	48.4	40.2	< 0.0001
[95% CI]c	[0.5245, 0.5744]	[0.6573, 0.7335]	[0.5209, 0.6499]	[0.4113, 0.5577]	[0.3607, 0.4439]
Patient fatigue, N = 981
%	47.7	56.8	57.3	42.4	36.8	< 0.0001
[95% CI]c	[0.4454, 0.5089]	[0.5146, 0.6206]	[0.4881, 0.6557]	[0.3361, 0.5156]	[0.3185, 0.4205]

CI confidence interval, LDA low disease activity, MCID minimum clinically important difference, mHAQ modified Health Assessment Questionnaire, M/HDA moderate or high disease activity, VAS visual analog scale

^aCounts may be reduced because of missing data for some variables (e.g., patient fatigue was not included in the Corrona RA questionnaire until October 2010)

^bStatistical significance of comparisons across disease activity groups did not change after adjustment for baseline value of the corresponding outcome. Unadjusted and adjusted regression coefficients shown in Supplemental Table 2

^c95% CI is shown as a proportion; the point estimate is shown as a percentage